Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study.
Détails
Etat: Public
Version: de l'auteur⸱e
Licence: Non spécifiée
ID Serval
serval:BIB_D9D07784DA58
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study.
Périodique
Nutrients
ISSN
2072-6643 (Electronic)
ISSN-L
2072-6643
Statut éditorial
Publié
Date de publication
28/06/2022
Peer-reviewed
Oui
Volume
14
Numéro
13
Pages
2683
Langue
anglais
Notes
Publication types: Journal Article ; Randomized Controlled Trial
Publication Status: epublish
Publication Status: epublish
Résumé
The vitamin D and microRNA (miR) systems may play a role in the pathogenesis of cardiometabolic disorders, including hypertension. The HYPODD study was a double-blind placebo-controlled trial aiming to assess the effects of cholecalciferol treatment in patients with well-controlled hypertension and hypovitaminosis D (25OHD levels < 50 nmol/L). In addition to this clinical trial, we also evaluated the effects of cholecalciferol and calcitriol treatment on miR-21 expression in vivo and in vitro, respectively. Changes in the cardiovascular risk profiles were evaluated in HYPODD patients treated with cholecalciferol (C-cohort) or with placebo (P-cohort). The miR-21circulating levels were measured in four C-cohort patients and five P-cohort patients. In vitro, the miR-21 levels were measured in HEK-293 cells treated with calcitriol or with ethanol vehicle control. Cholecalciferol treatment increased 25OHD levels and reduced parathormone, total cholesterol, and low-density lipoprotein cholesterol levels in C-cohort patients, whereas no significant changes in these parameters were observed in P-cohort patients. The miR-21 circulating levels did not change in the C- or the P-cohort patients upon treatment. Calcitriol treatment did not affect miR-21 levels in HEK-293 cells. In conclusion, hypovitaminosis D correction ameliorated the cardiovascular risk profiles in hypertensive patients treated with cholecalciferol but did not influence the miR-21 expression.
Mots-clé
Calcitriol/therapeutic use, Cardiovascular Diseases/drug therapy, Cholecalciferol/pharmacology, Cholecalciferol/therapeutic use, Cholesterol, Dietary Supplements, Double-Blind Method, HEK293 Cells, Heart Disease Risk Factors, Humans, Hypertension/drug therapy, MicroRNAs, Risk Factors, Vitamin D/therapeutic use, Vitamin D Deficiency/drug therapy, Vitamins, calcitriol, cholecalciferol, clinical trial, hypertension, hypovitaminosis D, inflammation, miR-21
Pubmed
Web of science
Open Access
Oui
Création de la notice
18/07/2022 10:58
Dernière modification de la notice
03/08/2022 7:13